MARBOFLOXACIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H19FN4O4
Molecular Weight	362.3556
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CN1CCN(CC1)C2=C3OCN(C)N4C=C(C(O)=O)C(=O)C(C=C2F)=C34

InChI

InChIKey=BPFYOAJNDMUVBL-UHFFFAOYSA-N

InChI=1S/C17H19FN4O4/c1-19-3-5-21(6-4-19)14-12(18)7-10-13-16(14)26-9-20(2)22(13)8-11(15(10)23)17(24)25/h7-8H,3-6,9H2,1-2H3,(H,24,25)

HIDE SMILES / InChI

Description

Marbofloxacin is an anti-bacterial veterinary medication which is approved by FDA and EMEA for the treatment of bacterial diseases in dogs and cats. The drug exerts its action by inhibiting bacterial DNA gyrase.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial DNA gyrase 66	Inhibitor 8,297

Conditions

Condition	Modality	Highest Phase	Product
Skin infections 59	Curative	Approved 8,429	Zeniquin
Soft tissue infections 4	Curative	Approved 8,429	Zeniquin
Urinary tract infections (cystitis) 3	Curative	Approved 8,429	Zeniquin

PubMed

Show entries

Title	Date	PubMed
Determination of residues of enrofloxacin and its metabolite ciprofloxacin in biological materials by capillary electrophoresis.	2001 Aug 5	11499631
Activity and postantibiotic effect of marbofloxacin, enrofloxacin, difloxacin and ciprofloxacin against feline Bordetella bronchiseptica isolates.	2001 Jul 3	11356321
Evaluation of the clinical efficacy of marbofloxacin (Zeniquin) tablets for the treatment of canine pyoderma: an open clinical trial.	2001 Jun	11420932
A field comparison of the efficacy and tolerance of marbofloxacin in the treatment of bovine respiratory disease.	2001 Oct	11696086
Using nonaqueous capillary electrophoresis to analyze several quinolones in pig kidney samples.	2002 Feb	11870754

Showing 1 to 5 of 41 entries

Previous1 2 3 4 5…9Next

Patents

Sample Use Guides

In Vivo Use Guide

1.25 mg per pound (/lb) of body weight once daily, but may be increased to 2.5 mg/lb of body weight once daily.

Route of Administration: Other

In Vitro Use Guide

MIC50 values of marbofloxacin against pathogens isolated from skin, soft tissue and urinary tract infections in dogs were: Staphylococcus intermedius - 0.25 ug/ml, Escherichia coli - 0.03 ug/ml, Proteus mirabilis - 0.06 ug/ml, Beta-hemolytic Streptococcus, (not Group A or Group B) - 1 ug/ml, Streptococcus, Group D enterococcus - 1 ug/ml, Pasteurella multocida - 0.015 ug/ml, Staphylococcus aureus - 0.25 ug/ml, Enterococcus faecalis - 2 ug/ml, Klebsiella pneumoniae - 0.06 ug/ml.

Show entries

Name

Type

Language

MARBOFLOXACIN

Official Name

English

9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-7H-PYRIDO(3,2,1-IJ)(4,1,2)BENZOXADIAZINE-6-CARBOXYLIC ACID

Systematic Name

English

MARBOFLOXACIN [GREEN BOOK]

Common Name

English

MARBOFLOXACIN [MART.]

Common Name

English

marbofloxacin [INN]

Common Name

English

Showing 1 to 5 of 8 entries

Previous1 2Next

Show entries

Classification Tree

Code System

Code

PART 520 ORAL DOSAGE FORM NEW ANIMAL DRUGS

CFR

21 CFR 520.1310

Antibiotic

NCI_THESAURUS

C795

Fluoroquinolones

WHO-VATC

QJ01MA93

Showing 1 to 3 of 3 entries

Previous1Next

Show entries

Code System

Code

Type

Description

DRUG BANK

DB11426

PRIMARY

FDA UNII

8X09WU898T

PRIMARY

RXCUI

69256

PRIMARY

RxNorm

CAS

115550-35-1

PRIMARY

INN

6807

PRIMARY

Showing 1 to 5 of 15 entries

Previous1 2 3Next

ACTIVE MOIETY


					8X09WU898T

MARBOFLOXACIN

SALT/SOLVATE (PARENT)


					W3C3ZZ8R2D

Marbofloxacin hydrochloride